Apremilast 30mg Bid With Narrowband UVB in the Treatment of Plaque Psoriasis

Part of paid clinical trials in East Windsor, New Jersey.

Sponsor
Psoriasis Treatment Center of Central New Jersey
Study ID
NCT02412644
Phase
PHASE4
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

12 weeks open label with Otezla® and NUVB, followed by 6 month double blind Otezla® (apremilast) or placebo to subjects who obtain PASI 75 at week 12 of phototherapy

Key Dates

First listed
Apr 9, 2015
Start date
May 28, 2015
Status verified
Dec 2018
Primary completion
Jul 31, 2016
Completion
Jul 31, 2016

Study Design

Enrollment
29 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Active Comparator: Apremilast + apremilast
    apremilast 30mg bid for 12 weeks.followed by apremilast 30 mg bid for 24 weeks
  • Placebo Comparator: apremilast + placebo
    apremilast 30mg bid for 12 weeks followed by placebo bid for 24 weeks

Primary Outcome Measure

Number of Participants Maintaining Psoriasis Area Severity Index Score (PASI) 75 at Week 36 [ Time Frame: 36weeks ]

Locations (1)

FacilityCityStateZIPSite coordinators
Psoriasis Treatment Center of Central New JerseyEast WindsorNew Jersey08520-

Find similar trials in East Windsor, NJ

By condition
Psoriasis
By specialty
DermatologyRheumatologyAutoimmune disease
By research site
Psoriasis Treatment Center of Central New Jersey· East Windsor, NJ

Related Studies